These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19789841)

  • 1. Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts.
    Balandin TG; Edelweiss E; Andronova NV; Treshalina EM; Sapozhnikov AM; Deyev SM
    Invest New Drugs; 2011 Feb; 29(1):22-32. PubMed ID: 19789841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barnase as a new therapeutic agent triggering apoptosis in human cancer cells.
    Edelweiss E; Balandin TG; Ivanova JL; Lutsenko GV; Leonova OG; Popenko VI; Sapozhnikov AM; Deyev SM
    PLoS One; 2008 Jun; 3(6):e2434. PubMed ID: 18560598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunocytochemical visualization of P185(HER2) receptor by antibody fused with dibarnase and conjugate of barstar with colloidal gold].
    Ivanova IuL; Edelweiss EF; Leonova OG; Balandin TG; Popenko VI; Deev SM
    Mol Biol (Mosk); 2013; 47(5):806-17. PubMed ID: 25509353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of fusion protein 4D5 scFv-dibarnase:barstar-gold complex for studying P185HER2 receptor distribution in human cancer cells.
    Ivanova JL; Edelweiss EF; Leonova OG; Balandin TG; Popenko VI; Deyev SM
    Biochimie; 2012 Aug; 94(8):1833-6. PubMed ID: 22531627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel fully human antitumor immunoRNase resistant to the RNase inhibitor.
    Riccio G; D'Avino C; Raines RT; De Lorenzo C
    Protein Eng Des Sel; 2013 Mar; 26(3):243-8. PubMed ID: 23232187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu.
    Cao Y; Mohamedali KA; Marks JW; Cheung LH; Hittelman WN; Rosenblum MG
    Mol Cancer Ther; 2013 Jun; 12(6):979-91. PubMed ID: 23493312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
    Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
    Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B.
    Cheung LH; Zhao Y; Alvarez-Cienfuegos A; Mohamedali KA; Cao YJ; Hittelman WN; Rosenblum MG
    J Exp Clin Cancer Res; 2019 Jul; 38(1):332. PubMed ID: 31362764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and characterization of a recombinant human beta defensin 2 fusion protein targeting the epidermal growth factor receptor: in vitro study.
    Zhang M; Qiu Z; Li Y; Yang Y; Zhang Q; Xiang Q; Su Z; Huang Y
    Appl Microbiol Biotechnol; 2013 May; 97(9):3913-23. PubMed ID: 22903275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A fusogenic dengue virus-derived peptide enhances antitumor efficacy of an antibody-ribonuclease fusion protein targeting the EGF receptor.
    Kiesgen S; Liebers N; Cremer M; Arnold U; Weber T; Keller A; Herold-Mende C; Dyckhoff G; Jäger D; Kontermann RE; Arndt MA; Krauss J
    Protein Eng Des Sel; 2014 Oct; 27(10):331-7. PubMed ID: 25301960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F.
    Woitok M; Klose D; Niesen J; Richter W; Abbas M; Stein C; Fendel R; Bialon M; Püttmann C; Fischer R; Barth S; Kolberg K
    Cancer Lett; 2016 Oct; 381(2):323-30. PubMed ID: 27502168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas.
    De Lorenzo C; Arciello A; Cozzolino R; Palmer DB; Laccetti P; Piccoli R; D'Alessio G
    Cancer Res; 2004 Jul; 64(14):4870-4. PubMed ID: 15256457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced Tumor Volume and Increased Necrosis of Human Breast Tumor Xenograft in Mice Pretreated by a Cocktail of Three Specific Anti-HER2 scFvs.
    Nejatollahi F; Nadimi E; Noorafshan A; Moazen S; Alizadeh AM; Khalighfard S; Sahebkar A
    Curr Protein Pept Sci; 2024; 25(5):409-418. PubMed ID: 38018211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation.
    Wang JH; Forterre AV; Zhao J; Frimannsson DO; Delcayre A; Antes TJ; Efron B; Jeffrey SS; Pegram MD; Matin AC
    Mol Cancer Ther; 2018 May; 17(5):1133-1142. PubMed ID: 29483213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusion of apoptosis-related protein Cytochrome c with anti-HER-2 single-chain antibody targets the suppression of HER-2+ breast cancer.
    Lu D; Guo Y; Hu Y; Wang M; Li C; Gangrade A; Chen J; Zheng Z; Guo J
    J Cell Mol Med; 2021 Nov; 25(22):10638-10649. PubMed ID: 34697906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer.
    Zhou M; Wang X; Xia J; Cheng Y; Xiao L; Bei Y; Tang J; Huang Y; Xiang Q; Huang S
    Int J Nanomedicine; 2020; 15():3087-3098. PubMed ID: 32431503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells.
    De Lorenzo C; Nigro A; Piccoli R; D'Alessio G
    FEBS Lett; 2002 Apr; 516(1-3):208-12. PubMed ID: 11959134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.
    D'Avino C; Paciello R; Riccio G; Coppola C; Laccetti P; Maurea N; Raines RT; De Lorenzo C
    Protein Eng Des Sel; 2014 Mar; 27(3):83-8. PubMed ID: 24421342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.